Clinical Trials Browser

Has results × Rogaratinib × Genitourinary × Clear all

NCT03473756 2025-04-09

FORT-2

Phase 1 Completed

37 enrolled 15 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03410693 2022-09-28

FORT-1

Phase 2/3 Completed

175 enrolled 19 charts

Carcinoma, Transitional Cell

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Phase 1 Completed

168 enrolled 59 charts

GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms